

Strides receives USFDA approval for Loratadine OTC Softgel Capsules

Approval to strengthen company's private label portfolio for the US market

Product to be manufactured at the flagship facility in Bangalore

Bangalore, January 16, 2020 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for **Loratadine Softgel Capsules, 10 mg (OTC)** from the United States Food & Drug Administration (USFDA). The product is a generic version of Claritin® Liqui-Gels® Capsules, 10 mg, of Bayer HealthCare LLC.

Strides is focusing on building a private label business in the US by leveraging its portfolio of products across soft gels, tablets, capsules and other proprietary formats. **Loratadine Softgel Capsules, 10 mg (OTC)** is part of Strides niche and small volume product portfolio with limited competition in the US private label market. According to IRI data, the US market for Loratadine Softgel Capsules, 10 mg (OTC) is approximately US\$ 50 Mn with only one other generic approval. The product will be manufactured at the company's Oral dosage facility at Bangalore.

The company has 102 cumulative ANDA filings with USFDA of which 68 ANDAs have been approved and 34 are pending approval.

About Loratadine Softgel Capsules

Loratadine Softgel Capsules is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact:

Strides

Badree Komandur

Executive Director - Finance
+91 80 6784 0747

Investor Relations:

Kannan. N: +91 98450 54745
Vikesh Kumar: +91 80 6784 0827
Sandeep Baid: +91 80 6784 0791
Email: Sandeep.baid@strides.com

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)
CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,
Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta
Road, Bangalore – 560 076

PR Consultancy

Fortuna PR
K Srinivas Reddy: +91 90005 27213
srinivas@fortunapr.com

K Priya: +91 95354 25418
priya@fortunapr.com